Table V.

Proliferation of mononuclear cells in response to stimulation by mitomycin-treated DUOC-01 cell products in mixed lymphocyte cultures.

Cord No.	Responder			Fold increase
	[A] Autologous CB MNCs	[B] Random matched PB MNCs	[C] 4/6 HLA-matched CB MNCs	B/A	C/A	B/C
9442386	17,181 ± 1414	169,725 ± 21,668		9.9
6230351	4400 ± 407	230,930 ± 28,592		52.5
10600790	280 ± 40	6426 ± 3426		23
9491682	1968 ± 796	40,302 ± 790	2004	20.5	1	20.1
8499116	1189 ± 238	25,053 ± 1615	2551	21.1	2.1	9.8

Cord No. unit shows the CBU unit used to manufacture each batch of DUOC-01. In all experiments shown, stimulator cells were mitomycin-treated DUOC-01. In autologous combinations (column A), DUOC-01 and responding CB MNC were derived from the same cord. In random-match PB MNC combinations (column B), MNCs were prepared from randomly selected normal PB donors. In 4/6 HLA-matched CB-MNC combinations (column C), DUOC-01 and CB MNC responders were made from CBUs that were matched for both HLA-B alleles and both HLA-DR alleles but mismatched at both HLA-A alleles. Values are mean ± SD counts per minute of titrated thymidine incorporation. In last 3 columns, values are fold increase in proliferation for donor/responder combinations indicated.